

PATENT
Customer No. 22,852
Attorney Docket No. 6478.1463

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
C. Jane ROBINSON et al.) Group Art Unit: To Be Assigned
Serial No.: To Be Assigned) Examiner: To Be Assigned
Filed: Herewith)
For: Antithrombin III for Disorders)
Caused by Angiogenesis)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to examination of this application on its merits, please amend the application as follows:

IN THE ABSTRACT:

After line 5, delete "Antithrombin III for disorders caused by angiogenesis"

IN THE SPECIFICATION:

Page 5, line 17, please insert

--Brief Description of the Drawings

Fig. 1 shows the effect of the alpha and beta forms of antithrombin on HUVEC cell numbers in the presence of VEGF, as determined by crystal violet staining.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Fig. 2 shows the effect of different concentrations of antithrombin III on HUVEC proliferation as determined by an MTT assay.

Fig. 3 shows the effect of different concentrations of antithrombin III on CPAC proliferation as determined by an MTT assay.

Fig. 4 shows the effect of different concentrations of Kybernin®P on HUVEC proliferation as determined by an MTT assay.

Fig. 5 shows the effect of different concentrations of Kybernin®P on CPAC proliferation as determined by an MTT assay.

Fig. 6 shows the effect of different concentrations of Kybernin®P on HUVEC proliferation as determined by a BrdU assay.

Fig. 7 shows the effect of different concentrations of Kybernin®P on CPAC proliferation as determined by a BrdU assay.--

IN THE CLAIMS:

Please cancel claims 1-6 and add new claims 7-15, as follows:

7. (New) A method of prophylaxis for a disorder caused by angiogenesis or arteriogenesis comprising administering active antithrombin III to a patient in need thereof.

8. (New) A method of treating a disorder caused by angiogenesis or arteriogenesis comprising administering active antithrombin III to a patient in need thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

9. (New) The method as claimed in claim 7 or 8, wherein the α isoform of antithrombin III, the β isoform of antithrombin III, a mixture of the two isoforms, or a concentrate of antithrombin III, is administered.

10. (New) The method as claimed in claim 7 or 8, wherein the disorder is a retinopathy, neuropathy, or an infectious disease such as leprosy.

11. (New) The method as claimed in claim 7 or 8, wherein the disorder is a cancer.

12. (New) The method as claimed in claim 11, wherein the cancer is a cancerous ulcer or a metastasis of cancerous ulcer.

13. (New) The method as claimed in claim 7 or 8, wherein the disorder is rheumatoid arthritis, psoriasis, endometriosis, chronic bronchitis, or a chronic inflammation of the gastrointestinal tract.

14. (New) The method as claimed in claim 7 or 8, wherein the antithrombin III is prepared recombinantly or transgenically.

15. (New) The method as claimed in claim 7 or 8, wherein the antithrombin III is administered intravenously, subcutaneously, intramuscularly or topically.

REMARKS

Claims 1-6 have been cancelled without prejudice or disclaimer, and new claims 7-15 have been added to more particularly point out and distinctly claim the subject matter which Applicants regard as the invention.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Applicants respectfully request examination and timely allowance of the pending claims. Applicants submit that the pending claims are in condition for allowance, and request a prompt, favorable action on the merits.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 16, 2002

By: Carol P. Einaudi

Carol P. Einaudi
Reg. No. 32,220

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com